In osteoclasts or bone marrow stromal cells from patients with MM, ibrutinib downregulated the secretion of carcinogen-initiated chemokines and cytokines, including CCL3, TNFβ, APRIL, and CXCL12, blocked CXCL12-induced adhesion and migration of MM cells and reduced IL6-induced cell growth [101]. Here, CCL3 is linked to Miyoshi myopathy.